Allogeneic hematopoietic cell transplantation; the current renaissance.
Blood Rev. 2019; 34: 34-44
Oral graft-versus-host disease.
Dent Clin North Am. 2008; 52: 79-109
Characterization of oral involvement in acute graft-versus-host disease.
Biol Blood Marrow Transplant. 2014; 20: 1717-1721
Chronic graft-versus-host disease: current management paradigm and future perspectives.
Oral Dis. 2019; 25: 931-948
Oral chronic graft-versus-host disease: current pathogenesis, therapy, and research.
Oral Dis. 2013; 19: 327-346
Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study.
Blood. 2005; 105: 3802-3811
Japan Society for Hematopoietic Cell Transplantation. Continuing increased risk of oral/esophageal cancer after allogeneic hematopoi in adults in association with chronic graft-versus-host disease.
Ann Oncol. 2014; 25: 435-441
Oral care for hematopoietic stem cell transplantation patients: a narrative review.
Oral Health Prev Dent. 2019; 17: 413-423
and for the European Society for Blood and Marrow Transplantation (EBMT). The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies.
Bone Marrow Transplant. 2019; 54: 1575-1585
Allogeneic hematopoietic stem cell transplantation in the elderly.
Crit Rev Oncol Hematol. 2007; 64: 49-63
Lancet. 2009; 373: 1550-1561
A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease.
Nature. 1983; 302: 159-161
Oral complications of chronic graft-versus-host disease.
J Natl Cancer Inst Monogr. 2019; 2019
Classification systems for chronic graft-versus-host disease.
Blood. 2017; 129: 30-37
Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, IV: the 2014 Response Criteria Working Group report.
Biol Blood Marrow Transplant. 2015; 21: 984-999
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy.
Allergy Asthma Clin Immunol. 2013; 9: 30
Assessing the relationship between oral chronic graft-versus-host disease and global measures of quality of life.
Oral Oncol. 2015; 51: 944-949
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease, V: the 2014 Ancillary Therapy and Supportive Care Working Group report.
Biol Blood Marrow Transplant. 2015; 21: 1167-1187
Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.
Clin Oral Investig. 2011; 15: 127-139
Salivary gland involvement in chronic graft-versus-host disease: prevalence, clinical significance, and recommendations for evaluation.
Biol Blood Marrow Transplant. 2010; 16: 1362-1369
Superficial mucoceles in chronic graft-versus-host disease: a case report and review of the literature.
Gen Dent. 2009; 57: 82-88
Taste disorders following cancer treatment: report of a case series.
Support Care Cancer. 2019; 27: 4587-4595
Long-term oral complications of allogeneic haematopoietic SCT.
Bone Marrow Transplant. 2012; 47: 265-270
Oral disease profiles in chronic graft versus host disease.
J Dent Res. 2015; 94: 547-554
Oral verruciform xanthoma associated with chronic graft-versus-host disease: a report of five cases and a review of the literature.
Head Neck Pathol. 2011; 5: 193-198
Oral posttransplantation lymphoproliferative disorder: an uncommon site for an uncommon disorder.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008; 105: 59-64
Solid cancers after bone marrow transplantation.
N Engl J Med. 1997; 336: 897-904
Solid cancers after allogeneic hematopoietic cell transplantation.
Blood. 2009; 113: 1175-1183
Oral malignancies following HSCT: graft versus host disease and other risk factors.
Oral Oncol. 2005; 41: 865-877
Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes.
Bone Marrow Transplant. 2011; 46: 884-891
Clinical presentation and management of mTOR inhibitor-associated stomatitis.
Oral Oncol. 2011; 47: 998-1003
Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
Br J Haematol. 2019; 185: 784-788
Cyclosporine-induced gingival hypertrophy.
JAMA Dermatol. 2019; 155: 487
and Fungal Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO). A systematic review of oral fungal infections in patients receiving cancer therapy.
Support Care Cancer. 2010; 18: 985-992
Oral complications in hematopoietic stem cell recipients: the role of inflammation.
Mediators Inflamm. 2014; 2014: 378281
American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update.
J Oral Maxillofac Surg. 2014; 72: 1938-1956
How we treat oral chronic graft-versus-host disease.
Blood. 2012; 120: 3407-3418
Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium.
Bone Marrow Transplant. 2013; 48: 1123-1128
Economic and practical considerations in the treatment of oral mucosal chronic graft-versus-host disease.
Biol Blood Marrow Transplant. 2018; 24: 1748-1753
Treatment of oral mucosal manifestations of chronic graft-versus-host disease: dexamethasone vs. budesonide.
Expert Opin Pharmacother. 2017; 18: 235-242
Photobiomodulation therapy in the management of chronic oral graft-versus-host disease.
Support Care Cancer. 2017; 25: 357-364
CO2 laser in oral graft-versus-host disease: a pilot study.
Bone Marrow Transplant. 2003; 32: 1031-1034
Basic oral care for hematology-oncology patients and hematopoietic stem cell transplantation recipients: a position paper from the Joint Task Force of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) and the European Society for Blood and Marrow Transplantation (EBMT).
Support Care Cancer. 2015; 23: 223-236
A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the World Workshop on Oral Medicine VI.
Drugs R D. 2017; 17: 1-28
Sialometrical and sialochemical analysis of patients with chronic graft-versus-host disease: a prolonged study.
Cancer Invest. 2003; 21: 34-40
Pilocarpine hydrochloride relieves xerostomia in chronic graft-versus-host disease: a sialometrical study.
Bone Marrow Transplant. 1999; 23: 1007-1011
Intraoral electrostimulator for xerostomia relief: a long-term, multicenter, open-label, uncontrolled, clinical trial.
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 113: 773-781
Extensive dental caries in patients with oral chronic graft-versus-host disease.
Biol Blood Marrow Transplant. 2012; 18: 1573-1579
Remineralization therapies for initial caries lesions.
Curr Oral Health Rep. 2015; 2: 95-101
Oral adverse effects of drugs: taste disorders.
Oral Dis. 2020; 26: 213-223
Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial.
Ann Oncol. 2011; 22: 2086-2093
Photobiomodulation therapy alleviates tissue fibroses associated with chronic graft-versus-host disease: two case reports and putative anti-fibrotic roles of TGF-β.
Photomed Laser Surg. 2018; 36: 92-99
Chronic graft-versus-host disease (GVHD) in children.
Pediatr Clin North Am. 2010; 57: 297-322
Oral chronic graft-versus-host disease in pediatric patients after hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2005; 11: 721-731
Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management.
Support Care Cancer. 2000; 8: 353-365
Periodontal disease might be a risk factor for graft versus host disease: a systematic review.
Crit Rev Oncol Hematol. 2020; 147: 102878